Core Viewpoint - The company, Meisi Health (02138.HK), anticipates a decline in financial performance for the six months ending September 30, 2025, based on preliminary unaudited consolidated management accounts Group 1: Financial Performance Expectations - Revenue for the reporting period is expected to decrease by no more than 10% compared to approximately HKD 2.063 billion for the corresponding period ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% compared to approximately HKD 247.9 million for the same period [1] - Net profit is anticipated to decrease by no more than 90% compared to approximately HKD 40.3 million for the corresponding period [1] Group 2: Reasons for Decline - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China and increased outbound travel, has weakened local demand for discretionary medical and aesthetic services [1] - Certain medical assets sold in the latter half of the previous fiscal year are no longer included in the financial statements, resulting in no revenue contribution for the reporting period [1] - A less favorable service mix with a decrease in the proportion of high-margin discretionary services [1] - Declining revenue has led to weakened operating leverage [1] Group 3: Financial Position - The overall asset-liability situation of the company remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [2]
医思健康(02138.HK)盈警：预计中期纯利同比减少不多于90%